Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2466 (LINC02466)
- Target
- LINC02466
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-protein coding RNA (lincRNA)
01
Overview
Long intergenic non-protein coding RNA 2466 (LINC02466) is a long non-coding RNA transcript with elevated expression in hepatocellular carcinoma (HCC) tissues compared to adjacent normal tissues, and its upregulation is associated with poor prognosis and more aggressive disease features. LINC02466 drives tumor progression mainly by promoting the proliferation, cell cycle progression, and stemness of liver cancer cells, which it achieves through modulation of the mTOR signaling pathway. Silencing LINC02466 suppresses oncogenic phenotypes, supporting its candidacy as a potential molecular target and biomarker for HCC. As with most lncRNAs, LINC02466 does not encode a protein and functions primarily at the RNA level, participating in regulatory networks within the cell.
- Other names
- LINC02466
02
Mechanism of action
Targeting the mTOR signaling pathway to inhibit LINC02466-mediated tumor promotion and stemness
03
Biological functions
Regulation of cell proliferationRegulation of cell cycle progressionMaintenance of stemness features in cancer cellsRegulation of cellular signaling pathways, including the mTOR signaling pathway
04
Disease associations
Cancer (specifically, hepatocellular carcinoma / primary liver cancer)
05
Safety considerations
Not directly reported; as a non-coding RNA target, general challenges include delivery, off-target effects, and functional redundancy in lncRNA networks
06
Interacting drugs
mTOR pathway inhibitors (e.g., rapamycin, also known as RAPA, shown to reverse effects of LINC02466 overexpression in vitro)
07
Biomarkers
LINC02466 expression level (biomarker for hepatocellular carcinoma diagnosis, prognosis, and possibly for therapeutic response)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2466 (LINC02466).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2466 (LINC02466).